Table: Aska Pharmaceutical -Q1 group results

ASKA Pharmaceutical Holdings

03/08/2020 07:00

Aug 3 (Reuters)- 
             Aska Pharmaceutical Co Ltd 
             CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)                
                 3 months ended      3 months ended       Year to 
                Jun 30, 2020        Jun 30, 2019     Mar 31, 2021 
                   LATEST             YEAR-AGO          LATEST    
                   RESULTS             RESULTS         FORECAST   
  Sales             13.71               13.99            53.00    
                 (-2.0 pct)          (+9.6 pct)       (+0.9 pct)  
  Operating        898 mln             837 mln            2.00    
                 (+7.2 pct)          (-31.2 pct)      (+32.7 pct) 
  Recurring        987 mln             969 mln            1.90    
                 (+1.8 pct)          (-28.4 pct)      (+10.8 pct) 
  Net              739 mln             563 mln            1.50    
                 (+31.1 pct)         (-46.9 pct)     (+131.1 pct) 
  EPS             26.09 yen           19.96 yen        52.95 yen  
  Ann Div                             17.00 yen        14.00 yen  
  -Q2 div                             7.00 yen         7.00 yen   
  -Q4 div                             10.00 yen        7.00 yen   
  
  NOTE - Aska Pharmaceutical Co Ltd. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4514.T